MultiPark Innovation outcomes

MultiPark’s innovation grants intend to foster translation of scientific discoveries to inventions that can be protected by patents to yield societal impact in the long term. Since 2011, MultiPark has funded 21 innovation projects with a total of 3.8 MSEK.

So far, the innovation support has sparked remarkable achievements: 

• 4 discoveries commercialized
• 6 patents filed
• 4 companies established
• 2 proprietary algorithms developed

Regardless of the results of the projects, the grants have stimulated the exposure of our researchers to the innovation process. Several projects have resulted in collaborations with pharmaceutical companies, and most projects resulted in publications in high-impact journals.

Currently, four grants have contributed to commercializing discoveries in the following areas: Alzheimer’s Disease Therapeutics, Gene and Cell Therapies targeting Parkinson´s Disease and Huntington’s disease, and a pharmacological Restorative Stroke Therapy.

The supported projects have resulted in the establishment of the following companies: Brave Bioscience Inc., Cell Invent AB, Dyno Therapeutics INC, Brave Bioscience Inc., Sinntaxis AB. In addition to supporting the development of novel therapies, the grant indirectly benefits society by generating tax revenues and employment outside of academia.

Moreover, algorithms have been developed for analyzing therapeutic effects in humans and rodents.

Also, the results of the MPI grants were a prerequisite for funding from other granting bodies such as VINNOVA or private investors.